 0001493152-17-003195.txt : 20170331 0001493152-17-003195.hdr.sgml : 20170331 20170331155352 accession number:		0001493152-17-003195 conformed submission type:	sc 13d public document count:		1 filed as of date:		20170331 date as of change:		20170331 subject company:	 	company data:	 		company conformed name:			positiveid corp 		central index key:			0001347022 		standard industrial classification:	laboratory analytical instruments [3826] 		irs number:				061637809 		state of incorporation:			de 		fiscal year end:			1231 	filing values: 		form type:		sc 13d 		sec act:		1934 act 		sec file number:	005-82925 		film number:		17730207 	business address:	 		street 1:		1690 south congress avenue 		street 2:		suite 200 		city:			delray beach 		state:			fl 		zip:			33445 		business phone:		561-805-8008 	mail address:	 		street 1:		1690 south congress avenue 		street 2:		suite 200 		city:			delray beach 		state:			fl 		zip:			33445 	former company:	 		former conformed name:	verichip corp 		date of name change:	20051215 filed by:		 	company data:	 		company conformed name:			caragol william j 		central index key:			0001380465 	filing values: 		form type:		sc 13d 	mail address:	 		street 1:		1690 south congress avenue 		street 2:		suite 200 		city:			delray beach 		state:			fl 		zip:			33445 sc 13d 1 sc13d.htm united states securities and exchange commission washington, d.c. 20549 schedule 13d under the securities exchange act of 1934 (amendment no. )* positiveid corporation (name of issuer) common stock - $0.0001 par value (title of class of securities) 73740j 407 (cusip number) william j. caragol 1690 south congress avenue, suite 201 delray beach, florida 33445 561-805-8008 (name, address and telephone number of person authorized to receive notices and communications) march 29, 2017 (date of event which requires filing of this statement) if the filing person has previously filed a statement on schedule 13g to report the acquisition that is the subject of this schedule 13d, and is filing this schedule because of &sect;&sect;240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ] note: schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. see rule 13d-7 for other parties to whom copies are to be sent. * the remainder of this cover page shall be filled out for a reporting person&rsquo;s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. the information required on the remainder of this cover page shall not be deemed to be &ldquo;filed&rdquo; for the purpose of section 18 of the securities exchange act of 1934 (&ldquo;act&rdquo;) or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act (however, see the notes). 1 names of reporting persons william j. caragol 2 check the appropriate box if a member of a group (see instructions) (a) [ ] (b) [ ] 3 sec use only 4 source of funds (see instructions) sc 5 check if disclosure of legal proceedings is required pursuant to items 2(d) or 2(e) [ ] 6 citizenship or place of organization united states of america 7 sole voting power number of 189,961,079,676 shares 8 shared voting power beneficially owned by 0 each 9 sole dispositive power reporting person 7,598,656,069 with 10 shared dispositive power 0 11 aggregate amount beneficially owned by each reporting person 189,961,079,676 12 check if the aggregate amount in row (11) excludes certain shares (see instructions) [ ] 13 percent of class represented by amount in row (11) 42.3% 14 type of reporting person (see instructions) in this schedule 13d relates to shares of common stock, par value $0.0001 per share (the &ldquo;shares&rdquo;) of positiveid corporation, a delaware corporation (the &ldquo;issuer&rdquo;), and is being filed by william j. caragol. the principal office of the issuer is located at 1690 s. congress avenue, suite 201, delray beach, fl 33445. item 2. identity and background the name of the reporting person is william j. caragol. his business address is 1690 south congress avenue, suite 201, delray beach, florida 33445 and his present principal occupation is chairman of the board of the issuer and chief executive officer of the issuer. mr. caragol is a citizen of the united states of america. mr. caragol has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) and was not, during the last five years, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws. item 3. source and amount of funds or other consideration on december 6, 2011, the compensation committee of the board of directors of the issuer approved a first amendment to employment and non-compete agreement, or the first amendment, between the issuer and mr. caragol in connection with mr. caragol&rsquo;s assumption of the position of chairman of the board effective december 6, 2011. the first amendment obligated the issuer to grant to mr. caragol an aggregate of 10,000 shares of restricted stock over a 4 year period as follows: (i) 2,000 shares upon execution of the first amendment, which shall vest on january 1, 2014, (ii) 2,000 shares on january 1, 2012, which shall vest on january 1, 2015, (iii) 2,000 shares on january 1, 2013, which shall vest on january 1, 2015, (iv) 2,000 shares on january 1, 2014, which shall vest on january 1, 2018, and (v) 2,000 shares on january 1, 2015, which shall vest on january 1, 2018. on january 7, 2016, the issuer granted to mr. caragol 500,000 options to purchase shares with an exercise price of $1.02 which vest; (i) 170,000 on january 1, 2017; (ii) 165,000 on january 1, 2018; (iii) 165,000 on january 1, 2019, as long-term equity compensation. on september 30, 2013, pursuant to a liability reduction plan, the issuer issued mr. caragol 250 shares of series i convertible preferred stock (&ldquo;series i&rdquo;). the series i had a stated value of $1,000 per share, and a dividend rate of 6.0% per year. the series i preferred stock had voting rights equivalent to twenty-five votes per common share equivalent. on january 14, 2014, the issuer granted to mr. caragol (i) 143 shares of series i pursuant to the amendment to mr. caragol&rsquo;s employment contract for 2014, whereby mr. caragol agreed to reduce his annual salary from $275,000 to $200,000; (ii) 100 shares of series i as compensation for out-of-pocket tax expense for previous equity awards; and (iii) 138 shares of series i as compensation for 2013. on january 12, 2015, the issuer granted to mr. caragol 225 shares of series i as compensation for 2014. on may 13, 2015, mr. caragol gifted 50 shares of series i to the caragol family irrevocable trust. on december 22, 2015, as compensation for 2016 the issuer granted to mr. caragol 150 shares of series i, at which time he owned a total of 956 shares of series i. on august 11, 2016, mr. caragol entered into an exchange agreement pursuant to which he exchanged 956 shares of series i, with a liquidation value of $1,076,458, for 1,076 shares of series ii convertible preferred stock (&ldquo;series ii&rdquo;), with an initial liquidation value of $1,076,000. the series ii has a stated value per share of $1,000, and a dividend rate of 6% per year. as with the series i preferred, the series ii preferred has 25 votes per common share equivalent. any shares of series i previously issued to mr. caragol are null and void and any and all rights arising thereunder were extinguished. from november 11, 2011 through august 18, 2016, the issuer did not have a class of securities registered pursuant to section 12 of the act. on august 19, 2016, the issuer filed a registration statement on form 8-a registering its class of common stock, par value $0.01 per share (this par value was reduced to $0.0001 per share on january 30, 2017), pursuant to section 12(g) of the act. mr. caragol was eligible to file a schedule 13g by august 29, 2016, because he did not acquire any securities following the registration. mr. caragol is now filing a schedule 13d because on march 29, 2017, as compensation for 2016, the issuer granted to mr. caragol 250 shares of series ii, at which time he owned a total of 1,327 shares of series ii. this acquisition, in the aggregate with all other acquisitions following march 29, 2016 (the twelve months immediately preceding the date of the most recent acquisition), is more than 7% of the voting power of the issuer. the series ii granted to mr. caragol has a stated value of $1,000 per share and as of march 29, 2017, is convertible into 7,598,441,400 shares, at a conversion price of $0.00018 per share. the conversion price of the series ii is calculated at 100% of the lowest daily volume weighted average price of the common stock during the subsequent 12 months following the issuance date. as each share of series ii holds 25 votes per share, the voting rights of mr. caragol&rsquo;s series ii total 189,961,035,008 shares. these shares constitute the majority of his beneficial ownership in the company. the series ii shares will vest on january 1, 2019. item 4. purpose of transaction the information set forth in item 3 is incorporated by reference into this item 4. except as set forth in this schedule 13d, mr. caragol does not have any present plans, arrangements or understandings that relate to or would result in any of the actions specified in clauses (a) through (j) of item 4 of schedule 13d. item 5. interest in securities of the issuer (a) mr. caragol beneficially owns 189,961,079,676 shares of the voting power of the issuer, representing 42.3% of the total voting power of the issuer, which includes 189,961,035,008 votes through his ownership of the series ii, 44,668 shares and 170,000 options that are currently exercisable for shares. as of march 29, 2017, there were 6,653,301,983 shares of our common stock issued and outstanding, and 3,247 shares of series ii preferred stock, which are convertible into 17,680,678,843 shares of common stock, issued and outstanding (the &ldquo;series ii conversion shares&rdquo;). as each series ii conversion share has the equivalent of 25 votes on each matter submitted to stockholders, the holders of the series ii preferred stock have control of 442,016,971,081 voting shares of the company. (b) mr. caragol has sole voting power over 189,961,079,676 shares. he has sole dispositive power over 7,598,656,069 shares, including 7,598,441,400 shares of series ii on an as-converted basis, 44,668 shares and 170,000 options that are currently exercisable for shares. see item 2 above for identity and background information regarding mr. caragol. (c) on march 29, 2017, as compensation for 2016 the issuer granted to mr. caragol 250 shares of series ii. (d) no other person is known to have a right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares beneficially owned by mr. caragol. (e) not applicable. item 6. contracts, arrangements, understandings or relationships with respect to securities of the issuer the information set forth in items 2 through 5 is incorporated by reference into this item 6. except as described in item 3 above, to the knowledge of mr. caragol, there are no contracts, arrangements, understandings or relationships (legal or otherwise), including but not limited to transfer or voting of any of the securities, finder&rsquo;s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies between mr. caragol and any other person, with respect to any securities of the issuer. item 7. material to be filed as exhibits not applicable signature after reasonable inquiry and to the best of my knowledge and belief, i certify that the information set forth in this statement is true, complete and correct. date: march 31, 2017 /s/ allison tomek, attorney-in-fact signature of reporting person 